Akesobio aims to complete the trials of its lead drug candidates and apply for approval to market them between the second half of this year and 2022. Photo: Handout
Akesobio aims to complete the trials of its lead drug candidates and apply for approval to market them between the second half of this year and 2022. Photo: Handout
IPO
Business

Chinese cancer drug firm Akesobio’s US$330 million IPO – Hong Kong’s largest this year – is oversubscribed 639 times by city’s investors

  • Akesobio’s HK$2.58 billion IPO sees HK$166.5 billion in investors’ funds locked up
  • Hard to know if popularity is driven by short-term speculation, analyst says

Eric Ng
Eric Ng

Updated: 10:39pm, 20 Apr, 2020

Why you can trust SCMP
Akesobio aims to complete the trials of its lead drug candidates and apply for approval to market them between the second half of this year and 2022. Photo: Handout
Akesobio aims to complete the trials of its lead drug candidates and apply for approval to market them between the second half of this year and 2022. Photo: Handout
READ FULL ARTICLE